Characterizing Sensitivity to Vincristine, Irinotecan, and Telomerase-targeted Therapy in Diffuse Anaplastic Wilms Tumor Patient-derived Xenografts☆
Topic overview
This study evaluates chemotherapy sensitivity and novel telomerase-targeted treatments in patient-derived xenograft models of diffuse anaplastic Wilms tumor, a high-risk pediatric kidney cancer with poor outcomes. The research explores vincristine and irinotecan responses alongside telomerase inhibition as potential therapeutic strategies for this challenging malignancy.
Key takeaways
- Diffuse anaplastic Wilms tumor (DAWT) has poorer prognosis compared to other Wilms tumor subtypes.
- Telomerase upregulation is a key mechanism in DAWT pathogenesis and represents a targetable vulnerability.
- Patient-derived xenografts enable preclinical testing of vincristine, irinotecan, and telomerase-targeted therapies for DAWT.
- Characterizing drug sensitivity in DAWT models may guide personalized treatment strategies for high-risk patients.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Characterizing Sensitivity to Vincristine, Irinotecan, and Telomerase-targeted Therapy in Diffuse Anaplastic Wilms Tumor Patient-derived Xenografts☆. GlobalCastMD Medical Library. 2024-12-26. https://dev.library.globalcastmd.com/article/9569?via_space=staycurrentmd
Comments